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Abstract
Recurrent copy number variations (CNVs) are common causes of neurodevelopmental disorders (NDDs) and associated
with a range of psychiatric traits. These CNVs occur at defined genomic regions that are particularly prone to recurrent
deletions and duplications and often exhibit variable expressivity and incomplete penetrance. Robust estimates of the
population prevalence and inheritance pattern of recurrent CNVs associated with neurodevelopmental disorders (NDD
CNVs) are lacking. Here we perform array-based CNV calling in 12,252 mother–father–child trios from the Norwegian
Mother, Father, and Child Cohort Study (MoBa) and analyse the inheritance pattern of 26 recurrent NDD CNVs in 13
genomic regions. We estimate the total prevalence of recurrent NDD CNVs (duplications and deletions) in live-born
children to 0.48% (95% C.I.: 0.37–0.62%), i.e., ~1 in 200 newborns has either a deletion or duplication in these NDDs
associated regions. Approximately a third of the newborn recurrent NDD CNVs (34%, N= 20/59) are de novo variants.
We provide prevalence estimates and inheritance information for each of the 26 NDD CNVs and find higher prevalence
than previously reported for 1q21.1 deletions (~1:2000), 15q11.2 duplications (~1:4000), 15q13.3 microdeletions
(~1:2500), 16p11.2 proximal microdeletions (~1:2000) and 17q12 deletions (~1:4000) and lower than previously
reported prevalence for the 22q11.2 deletion (~1:12,000). In conclusion, our analysis of an unselected and representative
population of newborns and their parents provides a clearer picture of the rate of recurrent microdeletions/duplications
implicated in neurodevelopmental delay. These results will provide an important resource for genetic diagnostics and
counseling.
Background
Copy number variants (CNVs) comprise a substantial fraction
of human genetic variation and their role in disease has been
studied extensively [1–3]. Recurrent CNVs have been
implicated in a range of rare genomic disorders and neuro-
developmental traits, e.g., 1q21.1 microdeletion- and
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microduplication syndrome, Williams-Beuren syndrome,
Prader–Willi/Angelman syndrome, 16p11.2 microdeletion-
and microduplication syndrome, and DiGeorge syndrome [4].
Specific regions of the genome are particularly prone to
recurrent deletions and duplications, typically through a
process characterized by nonallelic homologous recom-
bination (NAHR) between region specific low-copy
repeats (LCRs) [5]. Many such recurrent CNVs have
been found to cause genomic disorders, each character-
ized by distinct clinical features but with variable
expressivity and incomplete penetrance [6]. Throughout
the paper, we will hereafter refer to this set of CNVs as
recurrent CNVs associated with neurodevelopmental dis-
orders (NDD CNVs).
Albeit genomic disorders are clearly enriched in clini-
cally ascertained samples and firmly established to
increase the risk of neurodevelopmental disorders (NDDs),
the true prevalence and thus penetrance in the general
population are still uncertain for many CNVs [7–12]. Only
a few population-based studies have investigated this to
date, and there is a great need for unbiased prevalence
estimates [13–15]. To our knowledge, the largest popula-
tion study on recurrent CNVs was performed in the UK
Biobank, a population cohort with participants aged 40–69
years with a participation rate of only 5% [16]. Due to
ascertainment bias in most of these studies, it is not known
to what degree these prevalence estimates represent the
whole population, and the absence of parental CNV data
makes it impossible to infer their inheritance pattern. The
Norwegian Mother, Father, and Child Cohort Study
(MoBa) is a population-based pregnancy cohort study that
overcomes some of these challenges. MoBa was con-
ducted by the Norwegian Institute of Public Health that
recruited pregnant mothers from all over Norway from
1999 to 2008. DNA was obtained from both parents and
children and the cohort now includes data from more than
114,000 births [17]. Thus, high participation rate, rela-
tively low ascertainment bias, and the child–parent trio
(i.e., mother–father–child) design together with large
sample size make MoBa a unique resource for improving
our understanding of the population prevalence and
inheritance pattern for these recurrent CNVs.
In this study, we performed CNV analysis in 12,252 MoBa
trios and provide comprehensive analyses of the prevalence,
inheritance pattern and de novo rate of recurrent copy number
deletions and duplications implicated in neurodevelopmental
genomic disorders, i.e., microdeletions and microduplications
in the 1q21.1, 3q29, 7q11.23 (Williams-Beuren syndrome),
15q11.2 (Prader–Willi/Angelman syndrome (PW/AS)),
15q13.3, 16p11.2 distal and proximal, 17p13.3 (Miller-Dieker
syndrome), 17p11.2 (Smith-Magenis and Potocki-Lupski
syndrome), 17q12, 17q21.31 (Koolen-de Vries syndrome),
and 22q11.2 distal and proximal regions.
Materials and methods
The Norwegian Mother, Father, and Child Cohort
Study (MoBa)
The Norwegian Mother, Father, and Child Cohort Study
(MoBa) is a population-based pregnancy cohort study
conducted by the Norwegian Institute of Public Health [17].
Participants were recruited from all over Norway from 1999
to 2008. The pregnant women were invited to participate
before the 17th week of pregnancy, and 41% of women
consented to participation. The cohort now includes
114,500 children, 95,200 mothers and 75,200 fathers. The
current study is based on version 9 of the quality-assured
data files released for research. The establishment of MoBa
and initial data collection were based on a license from the
Norwegian Data Protection Agency and approval from The
Regional Committees for Medical and Health Research
Ethics. The MoBa cohort is based on regulations of the
Norwegian Health Registry Act. The current study was
approved by The Regional Committees for Medical and
Health Research Ethics (2015/2055).
Genotyping, quality control, CNV calling, and
filtering
SNP-based genotyping and quality control (QC) have been
described elsewhere [18]. In summary, MoBa1 data (9508
trios) were genotyped using Illumina’s HumanCoreExome-
12 v.1.1 and HumanCoreExome-24 v.1.0 arrays, while
MoBa2 data (5274 trios) were genotyped on Illumina’s
Global Screening Array v.1.0. Variants with call rate <98%
and out of Hardy–Weinberg equilibrium (P < 1.00E−06)
were excluded. Individuals with call rate <98%, excessive
heterozygosity (>4 standard deviations above the mean
heterozygosity in the sample) and non-Norwegian ancestry
were removed as well. Pairs of individuals with PI_HAT >
0.1 in identity by descent calculations were QC-ed by
keeping a random individual and removing the other one, in
each pair.
CNV-based genotyping and QC. The Log R Ratio (LRR)
and B Allele Frequency (BAF) values were extracted using
GenomeStudio (version v.2011.1 for discovery and v.2.0.3
for replication) (https://www.illumina.com/techniques/
microarrays/array-data-analysis-experimental-design/
genomestudio.html). The CNVs were called using
PennCNV, followed by the PennCNV trio module (version
1.0.3 for discovery and 1.0.4 for replication) [19] using
default settings. The merging of adjacent CNV fragments
was done using clean_cnv.pl script of PennCNV suit,
controlling for the efficiency of merging by examining bed
tracks of CNV segments before and after the merging in the
UCSC Genome Browser. Sample-level filtering was done
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with recommended parameters, e.g., the Log R Ratio stan-
dard deviation (LRR_SD) < 0.3, BAF_drift < 0.001, abso-
lute value of wave factor (|WF|) < 0.05, number of CNV
calls < 100 (MoBa1) and <130 (MoBa2) to account for
slight differences in array densities. After the QC only high-
quality trios in which all three individuals passed the above
requirements were taken forward for further filtering (N=
7986 trios (Moba1), N= 4266 trios (MoBa2), median
LRR_SD= 0.103, and median number of CNV calls= 10).
The frequency filtering was done using PLINK version
1.07 [20] removing all calls that had a frequency >1% in the
parental set only (unrelated individuals). Next, all calls
overlapping centromeric or telomeric regions as well as
known copy number susceptible loci, e.g., immunoglobulin,
were removed. Among the remaining CNVs, only calls
spanning at least 100 kilo base pair (kb) and 10 markers
were retained for downstream analyses.
Definition and identification of recurrent NDD CNVs
After CNVs were called, merged and filtered based on
frequency and size, only CNVs located within regions of
known recurrent genomic syndromes were taken forward
for analysis. The intersection was done using BEDTOOLS
version 2.27.1 [21]. All candidate NDD CNVs were
visualized and manually inspected using scatter plots of raw
intensity value points (LRR and BAF values) along the
genomic axis, for all individuals in each trio in putative
CNVs and flanking regions, with help of the ggpubr
package [22] to: (1) assess the evidence for a CNV, (2)
identify the inheritance pattern, and (3) correct any erro-
neous breakpoints (one duplication of 22q11.2 in offspring
number 53 (o53) was extended based on the signal in the
flanks consistent with a continuation of a CNV). One off-
spring CNV (a duplication of 15q11.2–q13.1 in offspring
number 13 (o13)) showed BAF and LRR distributions
consistent with a mosaic copy number gain of maternal
origin as one possibility.
The parental origin of de novo events was possible to
resolve unambiguously for all but one event (a duplication
of 16p11.2. distal in offspring number 33 (o33)). For
deletions we used the infer_snp_allele.pl script from the
PennCNV package [19] and for duplications we developed
an inhouse script that assessed the parental origin of all
three alleles at each marker as described elsewhere [23].
CNVs spanning at least 50% of the reference NDD
region included in the statistical analyses in the study
(Supplementary File 1 for coordinates according to the
Genome Reference Consortium Human Build 37 (GRCh37)
and Supplementary File 2 for visualization of all CNVs
included in the final analyses). The final set of NDD CNVs
was deposited to dbVar under accession nstd192.
Prevalence estimates




where NCNVs refers to the total number of recurrent NDD
CNVs and Ntrios refers to the total number of complete
trios that passed the QC. The Wilson score interval test was
used to provide the 95% confidence intervals around the
prevalence estimates. For some of the investigated recurrent
CNVs, we found zero events among our 12,252 children.
Using the Wilson score interval test, we estimate the 95%
confidence interval for the prevalence for these CNVs to be
between 0 and 0.0003.
Two proportions Z-test was used to test for the differ-
ences between the total number of deletions and total
number of duplications. The transmission disequilibrium
test was performed according to [24] using the total number
of NDD CNVs in a mother and total number of maternally
inherited NDD CNVs in a child and the total number of
NDD CNVs in a father and total number of paternally
inherited NDD CNVs in a child.
Results
In this study we investigated recurrent CNVs that span
chromosomal regions known to be associated with NDDs
i.e., 1q21.1, 3q29, 7q11.23, 15q11.2–13.1, 15q13.3,
16p11.2 distal and proximal, 17p13.3, 17p11.2, 17q12,
17q21.31 and 22q11.2 distal and proximal (Supplementary
File 3).
The total number of Norwegian trios that passed QC was
12,252. After classification of CNVs and QC, 59 recurrent
NDD CNVs were observed in the offspring (Supplementary
File 2), of which 39 were identified as inherited and 20 were
identified as de novo variants (Table 1, Fig. 1). This pro-
vided an estimate for the total prevalence of recurrent NDD
CNVs in this birth cohort of 0.48% (95% confidence
interval (C.I.): 0.37%, 0.62%) or in other words, 1 in 200
children was born with a recurrent deletion or duplication in
these 13 regions known to be associated with NDDs.
A total of 25 events were deletions while 34 were
duplications. We observed a lower proportion of deletions
compared to duplications (12 deletions vs. 27 duplications)
among the inherited variants while the opposite trend was
noticed among the de novo calls (13 de novo deletions vs. 7
de novo duplications). As can be seen in Table 1, only the
difference observed between inherited deletions and dupli-
cation reached nominal significance (P= 0.02). Only one
de novo CNV was consistent with a mosaic event, a
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15q13.3 copy number gain of maternal origin (Supple-
mentary File 2, offspring o13, page 4).
Since MoBa is a study where both mother and father
were genotyped together with the offspring, we were able to
assess the parent-of-origin status of recurrent NDD CNVs
(Fig. 2). We observed a higher rate of maternal variants
among the inherited calls (24 vs. 15), contrary to de novo
variants for which recurrent NDD CNVs occurred in equal
numbers on both the maternally and paternally derived
chromosomes (10 vs. 9) (Fig. 2). For one de novo dupli-
cation we were not able to assign the parent-of-origin status.
We also assessed the number of recurrent NDD CNVs in
Fig. 1 Circular plot of recurrent CNVs implicated in NDDs iden-
tified in MoBa trios. The tracks from outer to inner circles: ANN
(annotation); DATA (our data): (1) ANN:Chromosomes on an ideo-
gram; (2) ANN:NDD-relevant reference intervals; (3) DATA:de novo
deletions; (4) DATA:de novo duplications; (5) DATA:inherited
deletions; (6) DATA:inherited duplications; (7) ANN:genes of interest;
(8) ANN:ClinGen Benign Loss cumulative track; (9) ANN:ClinGen
Benign Gain cumulative track; (10) ANN:ClinGen Pathogenic Loss
cumulative track; (11) ANN:ClinGen Pathogenic Gain
cumulative track.
Table 1 Cumulative prevalence estimates of recurrent NDD CNVs.
Counts Prev (95% C.I.) Two proportions Z-test
Recurrent CNVs Del Dup Total Del Dup Total Z score P value
All 25 34 59 20.4 (13.83, 30.11) 27.75 (19.87, 38.75) 48.16 (37.35, 62.06) −1.17 0.24
Inherited 12 27 39 9.79 (5.6, 17.11) 22.04 (15.15, 32.04) 31.83 (23.3, 43.48) −2.4 0.016
De novo 13 7 20 10.61 (6.2, 18.15) 5.71 (2.77, 11.79) 16.32 (10.57, 25.2) 1.34 0.18
Del copy number deletions, Dup copy number duplications, Prev prevalence in 10,000.
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mothers and fathers per region and calculated the cumula-
tive transmission rate of maternal and paternal CNVs
(55.81% vs. 34.09%) (Supplementary File 4 and Fig. 3).
The overall prevalence (and their corresponding 95% C.I.)
of events in mothers (0.35% (95% C.I.: 0.26%, 0.47%)) and
fathers (0.36% (95% C.I.: 0.27%, 0.48%)) were similar, but
lower than what was seen in children (0.48% (95% C.I.:
0.37%, 0.62%)).
Prevalence estimates
We next calculated prevalence estimates (with their corre-
sponding 95% C.I.) for each recurrent microdeletion and
microduplication located in the 1q21.1, 3q29, 7q11.23,
15q11.2, 15q13.3, 16p11.2, 17p11.2, 17p13.3, 17q12,
17q21.31, and 22q11.2 regions (Table 2). We did not
observe any events in the 7q11.23 (Williams-Beuren syn-
drome) region, 17p13.3 (Miller-Dieker syndrome) region,
17q21.31 (Koolen-de Vries syndrome) region, and 22q11.2
distal region, nor in the 17p11.2 region (Smith-Magenis and
Potocki-Lupski syndromes) (Table 2).
We noticed a tendency toward more maternally derived
than paternally derived recurrent CNVs for the 1q21.1 and
typical 0.6 mega base pair (Mb)/proximal 16p11.2 micro-
deletion and microduplication (Tables 3, 4, respectively). A
total of seven maternal and three paternal calls were
detected in the 1q21.1 region while nine maternal and two
paternal calls were detected in the 16p11.2 region (Tables 3,
4). All of the seven maternally derived 1q21.1 CNVs and
2/3 of the paternally derived events were inherited, and for
the 0.6Mb/proximal 16p11.2 region, 6/9 of the maternally
derived and 1/2 of the paternally derived CNVs were
inherited.
Discussion
In this study we estimated the prevalence and inheritance
pattern of the recurrent CNVs implicated in neurodevelop-
mental disorders (NDD CNVs) among 12,252
mother–father–offspring trios from the Norwegian Mother,
Father, and Child Cohort Study (MoBa). This is to our
knowledge the first study using population-scale unselected
parent–child trio CNV data. Here we estimated the total
prevalence of recurrent NDD CNV duplications and dele-
tions in Norwegian live-born children to 0.48% (95% C.I.:
0.37–0.62%). Approximately a third of the newborn
recurrent NDD CNVs (34.0%, (20/59)) were de novo var-
iants. Thus, our data suggest that ~1 in 600 children are
born with a de novo event in these regions, setting the
cumulative rate of recurrent NDD de novo CNVs to 0.16%
per live-born child.
Having established the cumulative rate of NDD CNVs in
children we were also able to compare these numbers with
their parents. Interestingly, mothers and fathers have similar





































Fig. 2 Parental origin of recurrent CNVs implicated in NDDs
identified in MoBa trios. The total number of NDD CNVs with
resolved parent-of-origin is 58 (for a single de novo duplication in
16p11.2 distal region it was not possible to resolve the inheritance
status).
Fig. 3 Transmission of
recurrent CNVs implicated in
NDDs identified in MoBa.
Parents label indicates number
of CNVs stratified on parental
status, transmitted label
indicates number of transmitted
NDD CNVs. Mat maternal
origin, Pat paternal origin,
* indicates P values from
transmission disequilibrium test
with one degree of freedom.
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mothers and fathers respectively, N= 12,252 trios, 0.35%
prevalence in mothers and 0.36% in fathers) and there is
little, if no, overall transmission bias of these parental CNVs
to their live-born children (45% transmission versus the
expected 50% under the assumption of no selection oper-
ating on these CNVs (P= 0.33)). However, from fathers
only, this number drops to 34% (15 of 44, P= 0.03). Hence
among inherited events, 61.5% are inherited from mothers
(25 of 39) (Table 3). This suggests that negative selection
might be acting more strongly on the fecundity of paternal
NDD CNV carriers, albeit considerably larger numbers are
needed before firm conclusions can be drawn.
Among newborns, there was a significantly lower rate of
inherited deletions compared to inherited duplications (12
vs. 27, P= 0.02, Table 1). This is consistent with an overall
generally milder expressivity (i.e., lower severity) of
duplications [4, 25, 26]. The same trend was not seen for de
novo events for which there were slightly more deletions
than duplications (13 vs. 6, P= 0.11). Thus, both the total
frequency of events (59 in newborns vs. 43 in mothers and
44 in fathers) and the ratio of deletions vs. duplications were
higher in newborns than in their parents. The 35% higher
frequency of NDD CNVs in newborns compared to parents
entering into the study illustrates the selection that is acting
against the group of recurrent NDD CNVs investigated in
this study.
Several studies have shown that de novo CNVs are more
often of paternal origin [27]. We do not observe this ten-
dency for this particular group of recurrent NDD CNVs (10
maternal vs. 9 paternal). Albeit the numbers are small, our
data supports a few previous studies suggesting that for
some recurrent NAHR-mediated CNVs, local gender spe-
cific recombination rates may be the determining factor for
putative gender bias [23, 28].
Below we summarize and discuss the key observations
for each individual region tested.
1q21.1 microdeletion/microduplications are known to be
associated with learning problems and sometimes intellec-
tual disability (ID), autism spectrum disorders (ASD),
schizophrenia (SCZ), and attention deficit hyperactivity
disorder (ADHD). Previous estimations have indicated that
the prevalence for deletions is between 1 in 4000 and 1 in
6800 among healthy adult controls [4, 16, 29]. Our results
suggest that in newborns, the number of deletion carriers is
~1 in 2000 (i.e., 0.05%) (Table 2), which is more common
than what has been previously thought. Our data for the
corresponding reciprocal duplication (prevalence of ~3 in
10,000) is however in line with previous estimates in the
same adult control samples. This supports the statement that
individuals with the 1q21.1 microduplication have less
symptoms and are more likely to participate in biobank
studies. Moreover, two out of six deletions are de novo. Of
the inherited variants, it is notable that only one out of nine
paternal duplications and deletions was transmitted to the
offspring (Supplementary File 4). We are however not
aware of previous claims of reduced paternal transmission
for 1q21.1 microdeletion/duplications and this is likely a
chance finding.
15q.11.2–13.1 microdeletions can cause Prader–Willi or
Angelman syndrome, two neurobehavioral disorders caused
by deletions of reciprocal imprinted genes. We did not
observe any deletions in this region. However, we detected
Table 3 Prevalence estimates
and inheritance status of
recurrent NDD CNVs spanning
the 1q21.1 region.
1q21.1
De novo Inherited Total
Mat Pat Mat Pat Mat Prev (95% C.I.) Pat Prev (95% C.I.)
Del 0 2 3 1 3 2.45 (0.83, 7.2) 3 2.45 (0.83, 7.2)
Dup 0 0 4 0 4 3.26 (1.27, 8.39) 0 0
TOTAL 0 2 7 1 7 5.71 (2.77, 11.79) 3 2.45 (0.83, 7.2)
Mat maternally derived, Pat paternally derived, Prev prevalence in 10,000, Del copy number deletions, Dup
copy number duplications.
Table 4 Prevalence estimates
and inheritance status of
recurrent NDD CNVs spanning
the 16p11.2 region.
16p11.2 proximal
De novo Inherited Total
Mat Pat Mat Pat Mat Prev (95% C.I.) Pat Prev (95% C.I.)
Dels 3 1 2 0 5 4.08 (1.74, 9.55) 1 0.82 (0.14, 4.62)
Dups 0 0 4 1 4 3.26 (1.27, 8.39) 1 0.82 (0.14, 4.62)
TOTAL 3 1 6 1 9 7.35 (3.87, 13.96) 2 1.63 (0.45, 5.95)
Mat maternally derived, Pat paternally derived, Prev prevalence in 10000, Del copy number deletions, Dup
copy number duplications.
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three maternally derived 15q.11.2–13.1 duplications (one
constitutional de novo duplication, one mosaic de novo gain
in the offspring, and one duplication transmitted from the
mother). The 15q duplication syndrome and related dis-
orders are caused by maternally derived copy number gains
at the PW/AS critical region and are associated with
hypotonia, ASD, language delay and mild to moderate ID,
even if the carrier mother is phenotypically normal [30].
Extra copies of this locus can result both from direct
duplications due to unequal crossovers between the flanking
LCRs, or LCR-based generation of an isodicentric super-
numerary chromosome 15 (idic(15)) containing the PW/AS
locus [31]. In the latter case, the locus copy number would
normally be four. Two of the events identified here are
clearly direct duplications. However, it is possible that the
third—a mosaic gain (Supplementary File 2, offspring o13
—page 4 top right), represents a mosaic form of idic(15).
15q13.3 microdeletions and the reciprocal duplication
are also associated with learning problems and sometimes
ID [32]. Some individuals with these CNVs experience
developmental problems in social interaction and commu-
nication such as speech delay (as seen in patients with ASD)
and a wide range of behavioral problems such as aggres-
sion, impulsive behavior and hyperactivity [33]. In the
15q13.3 region we found considerably higher prevalence
for deletions than what has been estimated previously. Our
data indicates that about 1 in 2500 children is born with the
deletion compared to previous estimates at around 1 in
40,000 [32]. We also note that among our MoBa parents,
the prevalence is similarly high (9 deletions in 24,502
parents: 0.04% prevalence, Supplementary File 4). The
numbers are similar also for duplications. Thus, these data
suggest that 15q13.3 microdeletions/duplications are asso-
ciated with lower penetrance and/or milder clinical pre-
sentation than previously appreciated. Although the primary
scope of this study is on the classical full-length recurrent
NDD CNVs, we presented data on the much smaller
“nested” CNV mainly restricted to the CHRNA7 and
OTUD7A genes in a separate track in Fig. 1 [34, 35]. This
CNV is often seen in clinical diagnostic testing, and our
results confirm that this event is indeed more common, but
restricted to duplications (14 duplications, all inherited)
with only 1 deletion (de novo) being detected in our sample.
This observation supports that this smaller duplication is
phenotypically neutral.
16p11.2 proximal (classical) microdeletions and dupli-
cations (of the typical ~0.6 Mb size) are associated with a
range of NDDs with very variable penetrance and pre-
sentation between individual carriers. Key characteristics
are developmental delay (often mild ID in the case of
deletions), especially in speech and language, and ASD, but
carriers also have significantly increased risk of SCZ,
ADHD, obesity (if deletions), and seizures [11, 36–38].
Previous reports have provided various estimates of the
prevalence of the deletions. In the Icelandic population they
found 3.5 deletions per 10,000 individuals [39]. We find a
similar but slightly higher prevalence (5 in 10,000) with 4
out of 6 deletions being de novo. In contrast, all duplica-
tions in our study were inherited. Furthermore, 3 out of 4 de
novo and 6 out of 7 inherited variants were of maternal
origin (Table 4), indicating a maternal bias. This result
provides further support to a previous study that showed
that 89% of all 16p11.2 proximal de novo deletions and
duplications in their clinical cohort were of maternal origin
[23]. In contrast to their ascertained case cohort, we found a
tendency of maternal bias for both de novo and inherited
16p11.2 deletions/duplications in newborns (Table 4). This
suggests that there might be a negative selection acting on
paternal fecundity in addition to increased maternal de novo
rate. This is consistent with results from Iceland showing
that subjects carrying the 16p11.2 deletion had significantly
fewer children than the general population and this effect
was most attenuated among males [39].
16p11.2 distal microdeletions and duplications have
been associated with learning problems, ASD, and obesity
with variable phenotype and most likely relatively low
penetrance [40, 41]. We observed 3 deletions spanning this
region, of which 1 was de novo. The prevalence (~1:4000)
was higher than what has been observed in other studies, for
example in the UK biobank (~1:10,000) [16]. For the
reciprocal 16p11.2 distal microduplications, we detected 8
duplications (2 de novo) in this region, which is again
higher than suggested previously, indicating that approxi-
mately 1 in 1500 people carries this microduplication.
Both 17q12 microdeletions and duplications can cause
syndromes with variable symptoms even among affected
members of the same family. The common abnormalities
associated with the 17q12 deletions are problems with
kidneys and urinary system, including kidney cysts and
maturity-onset diabetes of the young type 5 (MODY5),
hence 17q12 syndrome is also known as renal cysts and
diabetes syndrome [42]. 17q12 microdeletions are also
associated with developmental delay and psychiatric disease
of very variable penetrance [43]. Individuals with the 17q12
duplication syndrome might not exhibit any symptoms, or
they might have delayed development and mild ID. For
deletions, we found three in our sample, all de novos. This
sets the prevalence estimate to 2.5 events per 10,000 new-
borns, again considerably higher than previous indirect
estimates of the population prevalence (1/14,500 according
to [29]) and in biobank studies (1 in 156,000 UK biobank
participants) [16]. This may suggest that a considerable
number of 17q12 deletion carriers remain undiagnosed.
Duplications seem to be more commonly inherited [44] and
our prevalence estimate of 2 in 10,000 is more in line with
biobank data and is consistent with a milder phenotype.
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22q11.2 microdeletions can cause a range of symptoms
with variable expressivity previously described as DiGeorge
syndrome and velocardiofacial syndrome (MIM:188400;
MIM:192430). This microdeletion is reported as one of the
most common recurrent deletions in clinical cohorts and has
also been associated with a range of psychiatric disorders
including SCZ and ADHD [45]. We found only 1 carrier
(de novo) among the 12,252 offspring in this study. This is
considerably lower than what is the commonly cited figures
for the prevalence of the 22q11.2 deletion syndrome in the
literature of more than 1 per 2000 newborns [45] to 1 in
4000 [46, 47]. Our results suggest that the true prevalence
of the 22q11 deletion is lower, and more likely is around 1
in 12,000. The reciprocal duplication is more common in
our study. We observed two de novo and four inherited
events in 12,252 offspring. This is in line with a milder
phenotype/lower penetrance for duplications at this locus.
The study has both strengths and limitations. Although
we argue that MoBa as a birth cohort provides a good
representation of the general population and thus allows for
robust estimations of the CNV burden among newborns,
there are still some limitations to this study. Invitations to
participate were sent to 277,702 pregnant women before
their appointment around 17th week of pregnancy [17] and
41% participated in the study. Thus, there is a possible
selection bias related to recruitment. Potential self-selection
bias in MoBa has been studied by comparing the prevalence
estimates and associations of different exposure and out-
come variables between mothers who decided to participate
in MoBa and all women whose deliveries were registered in
the Medical Birth Registry of Norway in 2000–2006 [48].
Young women (<25 years of age), women living alone and
women with more than two children are less represented in
MoBa than in the general population (relative deviation
30–45). Similar trends were observed for smokers and
women with stillbirths and neonatal deaths (relative devia-
tion 22–43%) [48]. These deviations may indicate possible
socioeconomic gradient influencing prevalence estimates.
This trend may be further exacerbated through our trio
study design that requires active participation of both the
father (blood for DNA extraction) and mother. Hence it is
likely that there is a bias against putatively deleterious and
impairing CNVs in the parental generation. Consequently,
our estimates of the inherited events may be biased down-
wards compared to the total newborn population. However,
while the participation rate (41%) may indicate some
recruitment bias, it is still considerably higher than most
other comparable studies, such as a rate of 5% in the UK
Biobank study [16]. Furthermore, since mothers were
recruited already at pregnancy week 17, the prevalence
estimates of de novo events should be more robust against
selection biases. And finally, unique to this study, MoBa
recruited both mothers and fathers. This allowed us to
determine the inheritance pattern and assess the parental
origin of the recurrent NDD CNVs in children and to cal-
culate the transmission rate of the events from mothers and
fathers.
By taking advantage of the trio study design of MoBa,
we have provided improved prevalence estimates and
inheritance details of 26 recurrent microdeletions and
duplications associated with NDDs and psychiatric traits.
These results should provide an important resource for
clinical genetic diagnostics and increased insight of the
genomic properties of this important class of variants.
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